Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which statin works best for HIV patients with high cholesterol?

NCT ID NCT00117494

Disease control Sponsor: French National Agency for Research on AIDS and Viral Hepatitis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two statin drugs, rosuvastatin and pravastatin, in 86 people with HIV who also had high cholesterol. The goal was to see which drug lowered LDL (bad) cholesterol better and was safer when taken with HIV medications. Participants took one of the two statins for 45 days, and researchers measured changes in cholesterol levels and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rosuvastatin and pravastatin (statin drugs)
What this could lead to
If one statin works better, it could offer a safer, more effective way to manage cholesterol in people with HIV.
What could go wrong
This is a small, completed Phase 4 trial with only 86 participants. Results may not apply to all HIV patients, and statins can have side effects like muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

86 people

Start date

Oct 2005

Finished

Jun 2007

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Fasting LDL cholesterol over 4.1 mmol/L (1.6 g/l) * Blood triglycerides over 8.8 mmol/L (8 g/l) * HIV-1 infection * Viral load above or equal to 10.000 copies/ml * Stable antiretroviral regimen for past two months Exclusion Criteria: * Coronary disease * Genetic muscular disease * CPK over 5N * Hepatic or renal insufficiency * Alcohol intake more than 40g/d * Hypothyroidism * Pregnancy and breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infections Hyperlipidemia

Contacts and locations

Locations

  • service de Médecine Interne Hopital Hotel Dieu

    Paris, 75004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.